AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 82 min read$SRRK

Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval

Scholar Rock (SRRK) resubmitted its European application for apitegromab, a treatment for spinal muscular atrophy (SMA), after addressing a manufacturing issue. The resubmission includes a new facility and is supported by Phase 3 trial results showing motor function improvements. The EMA is expected to issue an opinion in 2027. SRRK shares are currently trading at $41.48, down 1.71%.

Original reporting
rttnews.com
Published Oct 8, 2026, 2:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval — source image
Source · rttnews.com
Decision brief

The 30-second read

$SRRKNeutralMed
01

Why it matters

The EMA resubmission signals a critical regulatory milestone that could expand market access in Europe, affecting the company's valuation.

02

Market read

Regulatory filing may drive short‑term price movement; longer‑term impact depends on EMA decision.

03

What to watch

Potential for faster EMA approval timeline given FDA clearance and existing Phase 3 data.

Relevance 7/10Novelty 7/10Timing: today

Background

Scholar Rock (SRRK) recently received FDA approval for apitegromab (ISEMBYLD) in the U.S. and is now seeking EMA approval for the same therapy.

Company-level read

Ticker impact

$SRRKNeutralHigh confidence
Context

Scholar Rock resubmitted its EMA Marketing Authorization Application for apitegromab, introducing a new fill‑finish facility after a prior withdrawal.

Expected impact

possible modest pressure as investors price in regulatory uncertainty and the need for approval.

Evidence & confidence

First report of the resubmission; biotech stocks typically react to EMA decisions, and the change of manufacturing site adds operational risk.

Market effects

Sector

May influence other SMA‑focused biotech firms as EMA scrutiny intensifies.

Regional

European biotech sector could see slight volatility pending the CHMP opinion.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If the new facility resolves prior compliance issues, the stock could rally on reduced risk.

Key entities

  • company
    Scholar Rock

    Biotech firm developing apitegromab for SMA.

  • regulator
    European Medicines Agency (EMA)

    Authority reviewing the marketing authorization application.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 8
$SRRKMed

Raymond James reiterates Scholar Rock stock rating on MAA resubmission

Raymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.

investing.com1 min
OCT 8
$SRRKMed

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (SRRK) resubmitted its Marketing Authorisation Application (MAA) for apitegromab to the European Medicines Agency (EMA) for treating spinal muscular atrophy (SMA). The resubmission includes an alternate fill-finish facility, aligning with EMA guidance. The company anticipates a CHMP opinion in H1 2027. Apitegromab, marketed as ISEMBYLD in the U.S., is the first muscle-targeted therapy to show motor function improvement in SMA patients.

biospace.com2 min
OCT 8
$SRRKMedAI 8/10

Scholar Rock resubmits EU application for SMA treatment

Scholar Rock (NASDAQ:SRRK) resubmitted its EU application for apitegromab, a treatment for spinal muscular atrophy, using an alternate fill-finish facility. The company withdrew its previous application due to GMP compliance issues. Scholar Rock anticipates a CHMP opinion in the first half of 2027. Apitegromab is FDA-approved in the U.S. under the brand name ISEMBYLD.

investing.com2 min
SEP 28
$BMYHighAI 8/10

FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals

Bristol Myers Squibb (BMY) awaits an FDA decision on Sept. 30 for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy. Egetis Therapeutics (EGTX) faces a Sept. 28 decision for Emcitate for MCT8 deficiency. Scholar Rock (SRRK), Biofrontera (BFRI), and Mirum Pharmaceuticals (MIRM) received early FDA approvals for their respective drugs. Mirum's shares rose 3% in pre-market trading.

newsable.asianetnews.com2 min